Abstract: The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occn-panty of co-receptor present on the cell, for example. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CCR5 and CXCR4 sequences.

Abstract: The present invention relates to a soluble binding complex comprising a soluble gp120 trimer, in which only two gp120 protomers have CD4 binding sites occupied by interconnecting CD4 mimetic moieties, thereby allowing for the exposure of CD4-induced epitopes on the mimetic-bound protomers and an unoccupied CD4 binding site on the third gp120 protomer.

Abstract: The present invention relates to antigen-Ig Ab fusion molecules and methods of using same, wherein antigen-Ig Ab fusion molecules include an antigen fused to an immunoglobulin molecule, fragment or variant thereof and wherein the fusing of the immunoglobulin molecule to the antigen does not alter the specificity or tertiary structure of important epitopes of the antigen. This method allows the direct quantification and isolation of antigen-specific B cells by flow cytometry in essentially any species.

Abstract: The present invention relates to compositions and methods of using same to direct an immune response thereby enhancing the efficacy of an antigen containing vaccine by combining a chemokine in conjunction with the vaccine, wherein the choice of the chemokine directs the immune response in either the Th1 or Th2 direction.

Abstract: The present invention relates to a composition and method for enhancing the efficacy of a vaccine in a subject treated with the vaccine by administering to the subject an antigen in conjunction with a chemokine.

Abstract: The present invention relates to compositions and methods of using same to direct an immune response thereby enhancing the efficacy of an antigen containing vaccine by combining a chemokine in conjunction with the vaccine, wherein the choice of the chemokine directs the immune response in either the Th1 or Th2 direction.

Abstract: The present invention relates to a composition and method for enhancing the efficacy of a vaccine in a subject treated with the vaccine by administering to the subject an antigen in conjunction with a chemokine.

Abstract: The present invention relates to a composition and method for enhancing the efficacy of a vaccine in a subject treated with the vaccine by administering to the subject an antigen in conjunction with a chemokine.

Abstract: The present invention is directed to the discovery of antibodies that will react to proteins or nucleic acids bound to particular crosslinkers, but not to the free crosslinkers or free proteins or nucleic acids. Monoclonal antibodies with such binding specificity have widespread applications in receptor-ligand binding, immunodiagnostic and nucleic acid diagnostics.

Abstract: The present invention relates to a composition and method for enhancing the efficacy of a vaccine in a subject treated with the vaccine by administering to the subject an antigen in conjunction with a chemokine.

Abstract: The present invention relates to therapeutic compositions of macrophage derived chemokine (MDC) and methods for treating and preventing infection by a lentivirus, particularly an immunodeficiency virus, particularly HIV, using MDC proteins, nucleic acids and/or derivatives or analogues thereof. The present invention further relates to methods for detection and prognosis of lenivirus infection, particularly HIV infection using MDC as a prognostic indicator. The present invention further provides MDC proteins, nucleic acids encoding such proteins, that have amino-terminal sequences that differ from other MDC isolates. Recombinant host cells and methods of production are also provided.

Abstract: A vaccine and a method of raising neutralizing antibodies against HIV infection. The vaccine comprises a complex of gp120 covalently bonded to CD4 or to succinyl concanavalin A. Also disclosed are immunological tests using the complex or antibody thereto for detection of HIV infection.

Abstract: The present invention is directed to the discovery of antibodies that will react to proteins or nucleic acids bound to particular crosslinkers, but not to the free crosslinkers or free proteins or nucleic acids. Monoclonal antibodies with such binding specificity have widespread applications in receptor-ligand binding, immunodiagnostic and nucleic acid diagnostics.

Abstract: A vaccine and a method of raising neutralizing antibodies against HIV infection. The vaccine comprises a complex of gp120 covalently bonded to CD4 or to succinyl concanavalin A. Also disclosed are immunological tests using the complex or antibody thereto for detection of HIV infection.

Abstract: The present invention provides therapeutic compositions of receptor ligand-containing antagonist complexes and methods of using them to treat diseases, disorders or conditions associated with the function or aberrant function of a cell surface receptor.

Abstract: The present invention is directed to a method of raising neutralizing antibodies against HIV using a complex of gp120 covalently bonded to CD4 or a complex of gp120 covalently bonded to succinyl concanavalin A.

Abstract: The present invention relates to therapeutic compositions and methods for treating and preventing infection by an immunodeficiency virus, particularly HIV infection, using chemokine proteins, nucleic acids and/or derivatives or analogues thereof.

Abstract: Neutralizing antibodies against HIV infection are provided. The antibodies are reactive with cryptic epitopes on gp120 and/or CD4 induced by the formation of immunogenic complexes comprising gp120 covalently bonded to CD4 or to succinyl concanvalin A.

Abstract: A vaccine and a method of raising neutralizing antibodies against HIV infection. The vaccine comprises a complex of gp120 covalently bonded to CD4 or to succinyl concanvalin A. Also disclosed are immunological tests using the complex or antibody thereto for detection of HIV infection.

Abstract: A vaccine and a method of raising neutralizing antibodies against HIV infection. The vaccine comprises a complex of gp120 bonded covalently to CD4 or to succinyl concanavalin A.